FUJIFILM Diosynth Biotechnologies’ Post

Breaking new ground in VGT development 🧬 High dose delivery has long been an industry bottleneck, but Fujifilm BSEL is leading the charge with a revolutionary continuous electroporation device. Historically hindered by low throughput and poor cell viability, this new technology promises to eliminate the need for chemically mediated transfection. Set to debut in our Texas demo labs in early 2025, this device is poised to boost vector productivity, streamline manufacturing, and make VGTs more economically viable. Read more here: https://lnkd.in/eFyTpTzW

We are delighted to announce we will be co-exhibiting at BIO Asia Taiwan, July 24-28, 2024, in Taiwan. Schedule a meeting with our team via One-to-One partnering or stop by the Fujifilm booth M208 to learn more about FUJIFILM Diosynth Biotechnologies’ capabilities and how we can help you advance and deliver tomorrow’s medicines. #BIOAsiaTaiwan #TaiwanEvents #PharmaIndustry #Biotech

Autoinjectors, traditionally used for diabetes and autoimmune conditions, are now expanding into oncology and metabolic disease markets, empowering patients to manage their treatments at home, reducing travel time and costs. FUJIFILM Diosynth Biotechnologies and SHL Medical have partnered to enhance drug delivery solutions, combining SHL's expertise in self-injection devices with FDB's robust manufacturing capabilities. This collaboration ensures patients receive high-quality, user-friendly autoinjectors quickly and safely, revolutionizing patient care. https://lnkd.in/ewcifZ_A #Autoinjectors #MetabolicDisease #DrugDelivery #PatientCare #MedicalDevices #HealthcareInnovation #Biotechnology #MedicalManufacturing

Want to stay up to date with the breaking news, a calendar of conferences and events, as well as thought pieces by leading industry experts? Make sure to subscribe to our monthly newsletter, and read the latest edition below!

As we celebrate America's independence with a spirit of unity, we want to wish all our American employees, clients, and associates a Happy 4th of July! May this day be filled with joy and memorable moments with loved ones. 🎇 #IndependenceDay #Celebrate

Successful delivery of a bispecific antibody therapeutic to patients necessitates a manufacturing strategy that can accommodate the unique size, structure, and complexity of these molecules to ensure quality. We can perform manufacturability assessments to help clients choose the most suitable candidate for cell line development (CLD) and de-risk the development process. Read our full article by Dr. Fay Saunders, Director of Mammalian Cell Culture, Process Development to find out more! https://lnkd.in/eZYr8wiz

This week our team in Holly Springs celebrated the groundbreaking of the $1.2B expansion at our Holly Springs, North Carolina site! This expansion is a critical component of our Partners for Life 2030 Strategy - representing a significant increase of our commercial capacity in the coming years. By leveraging our KojoX principle of modularity, we believe we will increase our speed to go-live through replicating facility design. We are very proud of how our Holly Springs site continues to transform the industry and support bringing life impacting medicines to our clients' patients! You can read more here: https://lnkd.in/ewVmJzJv #Pharma #Biotech #Biotechnologies #Healthcare